Abstract
A large proportion of ontology clinical trials have excluded patients with brain metastases (BM). The Food and Drug Administration recommends including them to construct the efficacy and safety profile. We aimed to assess the impact of relaxing brain metastases exclusion criteria on the colon cancer trials population by (1) identifying the proportion of colon cancer patients with BM, and (2) examining whether BM patients have poorer survival.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
